53388-86-6

Upstream product

• 78-84-2 isobutyraldehyde 
• 589-21-9 (4-bromophenyl)hydrazine 
• 1373751-89-3 1-azido-4-bromo-2-tert-butylbenzene 
• 622-88-8 4-bromophenylhydrazine hydrochloride 
• 6310-21-0 2-(1,1-dimethylethyl)-benzenamine 
• 850012-44-1 4-bromo-(2-tert-butyl)aniline 
• 16940-66-2 sodium tetrahydroborate 
• 866364-70-7 1-(5-bromo-3,3-dimethylindolin-1-yl)ethan-1-one 
• 16078-32-3 1-(3,3-dimethylindolin-1-yl)ethan-1-one 
• 1914-02-9 3,3-dimethylindoline 
• 19155-24-9 3,3-dimethyloxindole 
• 120902-45-6 5-bromo-3,3-dimethyl-1,3-dihydro-2H-indol-2-one 

Downstream Products

• 844901-54-8 5-Bromo-3,3-dimethyl-1-(4-nitrophenylsulphonyl)-2,3-dihydro-1H-indole 
• 645417-03-4 ethyl {4-[(5-bromo-3,3-dimethyl-2,3-dihydro-1H-indol-1-yl)sulfonyl]-2-methylphenoxy}acetate 
• 1613147-59-3 (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(3,3-dimethyl-2,3-dihydro-1H-indol-5-yl)pyridin-2-amine 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS

Provided are compounds represented by Formula I, wherein R1, R 2a, R 2b, R 2c, R 2d, R 3, R 4a, R 4b, A, L, X, Y, Z, and are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Formula I are BCR-ABL I nhibitors. BCR-ABL inhibitors are useful for the treatment of cancer and other diseases.

LIPOXYGENASE INHIBITORS

Various embodiments of the present disclosure are directed to compounds having Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), and/or pharmaceutically acceptable salts thereof. The compounds can be suitable for inhibiting lipoxygenases, and/or treating associated diseases, such as Alzheimer's disease. In some embodiments, the compounds may be administered to a patient as part of a pharmaceutical formulation.

Iron-Catalyzed Intramolecular Aminations of C(sp3)?H Bonds in Alkylaryl Azides

The nucleophilic iron complex Bu4N[Fe(CO)3(NO)] (TBA[Fe]) catalyzes the direct intramolecular amination of unactivated C(sp3)?H bonds in alkylaryl azides, which results in the formation of substituted indoline and tetrahydroquinoline derivatives.

Substituted ring compound and its method and use thereof

The invention provides a substituted cyclic compound as well as a use method and application thereof. The compound is a compound as shown in a formula (I) or stereoisomers, stereomers, tautomers, nitric oxides, solvates, metabolites and pharmaceutically acceptable salts or prodrugs of the compound as shown in the formula (I). The invention further provides a medicament composition containing the compound. The compound and the medicament composition are capable of regulating the activity of protein kinase in a biological sample body and are used for protecting, treating or relieving proliferative diseases of patients. The formula (I) is as shown in the specification.

4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS

The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

BICYLIC COMPOUNDS AS MODULATORS OF RORGAMMA

The present invention encompasses compounds of the formula (I): wherein the variables are defined herein which are suitable for the modulation of RORC and the treatment of diseases related to the modulation of RORC. The present invention also encompasses

INHIBITORS OF CYTOMEGALOVIRUS

Compounds of Formula (I) wherein R1, R2, R3A, R3B, Y, Z1 and Z2 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.

SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF USE

The present invention provides novel substituted alkynyl compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

Bicyclic indolinesulphonamide derivatives

The invention relates to novel bicyclic indoline sulfonamide derivatives of general formula (I), methods for the production thereof, and the use thereof in medicaments, especially as potent PPAR delta agonists for preventing and/or treating cardiovascular

Indolinesulphanilic acid amides as ppar-delta modulators

The invention relates to novel indolin-sulfanilic acid amides of general formula (I), methods for the production thereof, and the use thereof in medicaments, especially as potent PPAR delta agonists for preventing and/or treating cardiovascular diseases,